

Daily evidence digest

25 October 2021

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Dexamethasone dosage, heterologous vaccination with Vaxzevria and Comirnaty, climatic signatures in COVID-19 waves

Peer reviewed journals featured:

- A randomised clinical trial of 12mg versus 6mg of dexamethasone in COVID-19 adults with severe hypoxemia [here](#) and associated editorial [here](#)
- Observational studies on:
 - Heterologous Vaxzevria (AstraZeneca) / Comirnaty (Pfizer) vaccination [here](#) and associated commentary [here](#)
 - Climatic signatures in the different COVID-19 waves [here](#)
 - Racial and ethnic disparities in rates of COVID-19 in the US [here](#)
- Commentary on COVID-19 interventions in children [here](#)

Letters and correspondence discussed:

- SARS-CoV-2 neutralisation with Comirnaty (Pfizer) vaccine dose 3 [here](#)
- COVID-19 breakthrough infections in vaccinated healthcare workers [here](#)
- Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies [here](#)

Pre-peer review articles featured:

- Psychological, social, and financial impacts of COVID-19 on culturally and linguistically diverse communities in Australia [here](#)
- Third dose of Comirnaty (Pfizer) in SARS-CoV-2 spike IgG antibody titres [here](#)
- Transmission from fully vaccinated individuals in a large Delta outbreak in Massachusetts [here](#)
- Airborne SARS-CoV-2 transmission over distances greater than two metres [here](#)

News and blogs

- Vaccine effectiveness in preventing deaths from Delta variant [here](#)
- Antibody testing for SARS-CoV-2 immunity [here](#)

[Click here](#) to subscribe to the daily evidence digest.